|Bid||23.25 x 1100|
|Ask||23.28 x 1400|
|Day's range||22.65 - 23.60|
|52-week range||1.92 - 33.79|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.33|
Optimistic investors are bidding up shares of both companies, but which one is the better stock pick?
Over the five-year period leading up to 2020, Inovio Pharmaceuticals (NASDAQ: INO) delivered a positive return in just one year: In 2016, Inovio gained a little over 3%. The company has emerged as one of a handful of small drugmakers with promising COVID-19 vaccine candidates. Could buying Inovio stock now make you rich over the next several years?
Multiple drugmakers are scrambling to develop COVID-19 vaccine candidates. In terms of clinical progress, Moderna (NASDAQ: MRNA) appears to be neck-and-neck for the lead with a partnership between AstraZeneca and the University of Oxford. The U.S. biotech hopes to begin a pivotal late-stage study of its COVID-19 vaccine candidate mRNA-1273 later this month.
Shares of potential COVID-19 developers have surged with each bit of news. But one offers better prospects for investors.
What happened Inovio Pharmaceuticals (NASDAQ: INO) stock skyrocketed 82.7% in June, according to data from S&P Global Market Intelligence. The S&P 500 returned 2% last month. In July, shares of the coronavirus vaccine developer, however, have given back a chunk of last month's gain: Through Tuesday, July 7, they're down nearly 11%, while the broader market has returned just over 3%.
Inovio Pharmaceuticals (NASDAQ: INO) has been grabbing a lot of headlines over the past few weeks, mostly thanks to its involvement in the race to find a vaccine for COVID-19. The company claimed to have come up with its potential vaccine, INO-4800, in a mere three hours after Chinese researchers publicly published the genetic sequence of the SARS-CoV-2 virus that causes COVID-19. Inovio initiated a phase 1 clinical trial for this vaccine in early April.
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were bouncing back on Thursday after being clobbered earlier this week. The biotech stock still has a long way to go to make up its lost ground. Inovio's shares were down 37% this week as of the close on Wednesday.
If you only looked at stock performance, you might conclude that Inovio Pharmaceuticals (NASDAQ: INO) is a better coronavirus stock than Moderna (NASDAQ: MRNA). While Moderna's share price has more than tripled so far in 2020, Inovio stock has skyrocketed more than 700%. There's a strong case to be made that Moderna is actually the better pick of these two coronavirus-focused biotech stocks.
Pfizer (PFE) on Wednesday announced early positive results for the first phase of its coronavirus vaccine trial, sparking hopes that an effective treatment can help turn the tide amid an implacable surge in new infections.
As an early-stage trial, the study is only looking for data about INO-4800's safety and its immunogenicity -- i.e, its ability to trigger the desired immune response in the body. The interim data from the trial found no serious safety concerns associated with the vaccine -- it was "generally safe and well-tolerated." Importantly, 94% of them demonstrated an immune response six weeks after receiving the vaccine.
The vaccine, one of 17 being tested in humans and part of the Trump administration's Operation Warp Speed program, induced immune responses in 34 of the 36 healthy volunteers aged 18 to 50 years, Inovio said. The company, however, did not disclose more details on the exact response the vaccine induced, saying the full data will be published in a peer-reviewed medical journal later. Shares of the company fell 10.1% to $28.49 as Wall Street analysts said the initial data provided only a limited look into the vaccine's effects.
The analysts covering Inovio Pharmaceuticals, Inc. (NASDAQ:INO) delivered a dose of negativity to shareholders today...
(Bloomberg) -- Drug and vaccine makers working on Covid-19 medicines rallied after President Donald Trump hinted at a “big surprise” coming soon, while day traders continued to favor a handful of smaller developers.Vaxart Inc., which also said it made a deal to scale up production of its experimental vaccine, was among the standouts, gaining as much as 57% on Thursday. Lesser-known drug developers working on medicines for Covid-19, like microcap NanoViricides Inc., jumped as much as 25%, while CytoDyn Inc. surged 33%.Sorrento Therapeutics Inc. climbed 30% before paring its gain. The stock shot up and appeared on investor radars in May after the chief executive and founder touted early data on Fox News.Some Wall Street analysts have suggested that Trump may try to push through a vaccine before the November election to score a win in the eyes of voters, spurring concerns about safety and effectiveness. With a recent surge in U.S. Covid-19 cases, day traders are looking for potential winners, and more skilled investors are having trouble catching up.“I think we’re coming up with some great answers,” Trump said in reference to Covid-19 vaccines and treatments on Wednesday afternoon. “I think you’re going to have a big surprise, a beautiful surprise sooner than anybody would think.”Day traders have been been jumping into some lesser-known small cap vaccine makers. Inovio Pharmaceuticals Inc. and Novavax Inc. were among the most popular trades in the past 24-hours, according to data from RobinTrack, which tracks Robinhood accounts holding shares. The pair are also the biggest winners on the Russell 2000 so far this year.Novavax rose as much as 11% on Thursday. The stock has surged more than 1,950% in 2020. Inovio shares jumped as much as 25%, though the gain moderated after short-seller Citron Research tweeted the stock would drop. Moderna Inc., one of the leaders in the efforts to develop a vaccine, reversed course after an Axios report suggested the company may not have full rights over its shot.Benchmark analysts rushed to catch up to Inovio’s stock price, which has increased seven-fold this year, and raised their price target to $36 from $28 Thursday on “assumed favorable” data from the earliest results of its vaccine trial expected in the next few days.The jump in new cases may mean a “lowering the bar for anticipated efficacy for COVID-19 vaccines,” Benchmark said. Neither Inovio nor Novavax have had a product reach the market, though Novavax is expected to file for regulatory approval of its experimental inoculation for the flu soon.The pair took a small breather earlier this month when they weren’t named among potential candidates for the Trump administration’s Operation Warp Speed, but Wall Street analysts held out some hope that they could be among the program’s finalists.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The drug developer's shares rose nearly 13% to $17.27 before the opening bell. The funding from the DoD will be used to expand the manufacturing of a next-generation version of the company's Cellectra devices. The company began developing the devices in 2019 and has already begun initial production.
Novavax's (NVAX) coronavirus vaccine candidate NVX-CoV2373 enters clinical studies. The company also plans to file a BLA on its influenza vaccine candidate, NanoFlu.
The government is stepping up its efforts to fund vaccine studies and production for at least three of five frontrunner candidates — something that Dr. Anthony Fauci told Yahoo Finance will be worth its weight in gold in the long run.
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sinking 12.8% lower as of 3:27 p.m. EDT on Wednesday. Inovio's shares slipped earlier in the day following comments that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), made in an interview with JAMA editor Howard Bauchner. Fauci stated that he was concerned that COVID-19 vaccines likely won't provide a long period of immunity.
Inovio Pharmaceuticals (NASDAQ: INO) shares climbed 22.6% in May, according to data from S&P Global Market Intelligence, as investors cheered the rapid development of its coronavirus vaccine and as the company published positive preclinical data. Inovio in late April said it completed enrollment of 40 healthy volunteers in a phase 1 trial for its coronavirus vaccine and said it expects preliminary data in late June. The company last month announced the publication of preclinical data showing strong neutralizing antibody and T-cell immune responses in animal models.
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.